ATLANTA, GA – – (Globe Newswire – September 30, 2026) – – A shareholder class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex”) (NASDAQ: AVXL). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that:  (1) Anavex lacked adequate internal controls; (2) Anavex understated its potential regulatory challenges as a result of misconduct by former CEO Christopher Missling; and (3) as a result, Defendants’ statements about Anavex’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you purchased Anavex shares between November 26, 2025 and August 28, 2026, and experienced a loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832, or by visiting the firm’s website at www.holzerlaw.com/case/anavex-life-sciences/ for more information.

The deadline to ask the court to be appointed lead plaintiff in the case is November 30, 2026.